维护低剂量BRAF抑制和Rituximab在复发性毛细胞白血病中:一种治疗替代方案
Anshul Patel1, Sarina Koilpillai1, Cassie Nguyen2
1Hematology and Medical Oncology, Orlando Health Cancer Institute, Orlando, USA.
Cureus
|December 1, 2025
概括
毛细胞白血病 (HCL) 是一种罕见的癌症. BRAF V600E抑制剂和抗CD20单克隆抗体的联合治疗在复发患者中显示出有前途,实现了完全缓解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 毛细胞白血病 (HCL) 是一种罕见的B细胞瘤,通常用 purin 类似物治疗.
- 复发性或耐火性HCL由于对标准疗法的耐药性而构成治疗挑战.
- 与抗CD20抗体相结合的BRAF V600E抑制剂显示出在复发性HCL中具有持久反应的潜力.
研究的目的:
- 报告一个用新型组合疗法治疗的复发性和耐火性HCL病例.
- 为了评估vemurafenib和rituximab在患有高级HCL的患者中的疗效.
主要方法:
- 患者接受了初始高剂量的维穆拉菲尼布和利图西马布治疗3个月.
- 随后,该患者继续接受低剂量维穆拉菲尼布加上每月一次的修复药,持续近一年.
- 用形态和分子评估来监测反应.
主要成果:
- 最初的治疗导致了部分反应.
- 延长的低剂量维持疗法导致了完全的形态和分子缓解.
- 患者通过组合疗法获得了持久的反应.
结论:
- BRAF V600E抑制剂和抗CD20单克隆抗体的组合可以在复发性/耐药性HCL中诱导完整和持久的反应.
- 用低剂量的维护疗法Vemurafenib和Rituximab可能有效地实现长期缓解.
- 这一案例突出了对具有挑战性的HCL病例的潜在治疗策略.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


